Acellular pertussis vaccines--a solution to the pertussis problem

Area of Science:

• Immunology
• Vaccinology
• Microbiology

Background:

• Pertussis (whooping cough) data and immunization information are often misinterpreted.
• Pertussis mortality is underreported, and concerns about vaccine-induced brain damage are unfounded.
• Whole cell pertussis vaccines are generally effective, and acellular vaccines have a successful history, notably in Japan since 1981.

Purpose of the Study:

• To clarify the efficacy and safety of pertussis vaccines.
• To evaluate the components of acellular pertussis vaccines and their impact on efficacy.
• To propose strategies for the future control of pertussis.

Main Methods:

• Review of available data on pertussis and pertussis immunization.
• Analysis of pertussis vaccine efficacy studies.
• Evaluation of vaccine technology and antigen requirements.

Main Results:

• Most whole cell pertussis vaccines are effective, with no evidence of causing brain damage.
• Third-generation acellular pertussis vaccines require further understanding of optimal antigen composition.
• Vaccines containing pertactin and fimbrial antigens alongside LPF toxoid and FHA demonstrate superior efficacy compared to simpler formulations.

Conclusions:

• Pertussis is not solely caused by lymphocytosis-promoting factor (LPF) toxin.
• Multicomponent acellular pertussis vaccines are crucial for effective disease control.
• Universal childhood immunization coupled with adult booster doses is recommended to curtail pertussis incidence and circulation.